BCM
CARM

BlueCrest Capital Management’s Carisma Therapeutics CARM Stock Holding History

BlueCrest Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,250
Closed -$129K – 498
2019
Q1 		$129K Buy
+6,250
New +$108K 0.01% 1036

Other funds holding CARM

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

BlueCrest Capital Management's CARM Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Carisma Therapeutics (CARM) in Q2 2019, closing a stake of 6,250 shares — an estimated $129K sold.

BlueCrest Capital Management first reported a position in CARM in Q1 2019 and held it in 1 quarter. The position peaked at $129K in Q1 2019. 43 funds tracked by Wall St. Rank hold CARM as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Carisma Therapeutics position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 6,250 Carisma Therapeutics shares in Q2 2019, an estimated $129K.
  • BlueCrest Capital Management first reported a position in Carisma Therapeutics in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Carisma Therapeutics position peaked at $129K in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.